In vivo metal-catalyzed SeCT therapy by a proapoptotic peptide. Issue 37 (2nd September 2021)

• Record Type: Journal Article
• Authors: Ahmadi, Peni; Muguruma, Kyohei; Chang, Tsung-Che; Tamura, Satoru; Tsubokura, Kazuki; Egawa, Yasuko; Suzuki, Takehiro; Dohmae, Naoshi; Nakao, Yoichi; Tanaka, Katsunori
• Is Part Of: Chemical science. Volume 12:Issue 37(2021)
• Page Start: 12266
• Page End: 12273
• Publication Date: 2021-09-02
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1sc01784e
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : The combination of a proapoptotic peptide with covalent tagging and a carrier-Ru-complex inhibited tumor growth in mice after a single injection. Abstract : Selective cell tagging (SeCT) therapy is a strategy for labeling a targeted cell with certain chemical moieties via a catalytic chemical transformation in order to elicit a therapeutic effect. Herein, we report a cancer therapy based on targeted cell surface tagging with proapoptotic peptides (Ac-GGKLFG-X; X = reactive group) that induce apoptosis when attached to the cell surface. Using either Au-catalyzed amidation or Ru-catalyzed alkylation, these proapoptotic peptides showed excellent therapeutic effects both in vitro and in vivo . In particular, co-treatment with proapoptotic peptide and the carrier–Ru complex significantly and synergistically inhibited tumor growth and prolonged survival rate of tumor-bearing mice after only a single injection. This is the first report of Ru catalyst application in vivo, and this approach could be used in SeCT for cancer therapy.